Literature DB >> 30321784

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Francesca Palandri1, Giuseppe A Palumbo2, Massimiliano Bonifacio3, Massimo Breccia4, Roberto Latagliata4, Bruno Martino5, Nicola Polverelli6, Elisabetta Abruzzese7, Mario Tiribelli8, Maura Nicolosi9, Micaela Bergamaschi10, Alessia Tieghi11, Alessandra Iurlo12, Nicola Sgherza13, Francesco Cavazzini14, Alessandro Isidori15, Gianni Binotto16, Adalberto Ibatici17, Monica Crugnola18, Florian Heidel19, Costanza Bosi20, Daniela Bartoletti21, Giuseppe Auteri21, Lucia Catani21, Antonio Cuneo14, Franco Aversa18, Gianpietro Semenzato16, Michele Cavo21, Nicola Vianelli21, Giulia Benevolo9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30321784     DOI： 10.1016/j.leukres.2018.10.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  8 in total

1.  Disease Modification in Myelofibrosis: An Elusive Goal?

Authors:  Pankit Vachhani; Srdan Verstovsek; Prithviraj Bose
Journal:  J Clin Oncol       Date:  2022-01-27       Impact factor: 44.544

Review 2.  Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.

Authors:  Andrew T Kuykendall; Nathan P Horvat; Garima Pandey; Rami Komrokji; Gary W Reuther
Journal:  Cancers (Basel)       Date:  2020-08-14       Impact factor: 6.639

Review 3.  The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.

Authors:  Mario Tiribelli; Francesca Palandri; Emanuela Sant'Antonio; Massimo Breccia; Massimiliano Bonifacio
Journal:  Bone Marrow Transplant       Date:  2019-09-18       Impact factor: 5.483

Review 4.  Focus on Osteosclerotic Progression in Primary Myelofibrosis.

Authors:  Mariarita Spampinato; Cesarina Giallongo; Alessandra Romano; Lucia Longhitano; Enrico La Spina; Roberto Avola; Grazia Scandura; Ilaria Dulcamare; Vincenzo Bramanti; Michelino Di Rosa; Nunzio Vicario; Rosalba Parenti; Giovanni Li Volti; Daniele Tibullo; Giuseppe A Palumbo
Journal:  Biomolecules       Date:  2021-01-19

5.  Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.

Authors:  Francesca Palandri; Giuseppe Alberto Palumbo; Elena Maria Elli; Nicola Polverelli; Giulia Benevolo; Bruno Martino; Elisabetta Abruzzese; Mario Tiribelli; Alessia Tieghi; Roberto Latagliata; Francesco Cavazzini; Micaela Bergamaschi; Gianni Binotto; Monica Crugnola; Alessandro Isidori; Giovanni Caocci; Florian Heidel; Novella Pugliese; Costanza Bosi; Daniela Bartoletti; Giuseppe Auteri; Daniele Cattaneo; Luigi Scaffidi; Malgorzata Monica Trawinska; Rossella Stella; Fiorella Ciantia; Fabrizio Pane; Antonio Cuneo; Mauro Krampera; Gianpietro Semenzato; Roberto Massimo Lemoli; Alessandra Iurlo; Nicola Vianelli; Michele Cavo; Massimo Breccia; Massimiliano Bonifacio
Journal:  Blood Cancer J       Date:  2021-01-07       Impact factor: 11.037

Review 6.  How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Authors:  Nicola Polverelli; Mirko Farina; Mariella D'Adda; Enrico Damiani; Luigi Grazioli; Alessandro Leoni; Michele Malagola; Simona Bernardi; Domenico Russo
Journal:  Cells       Date:  2022-02-05       Impact factor: 6.600

Review 7.  The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.

Authors:  John O Mascarenhas; Srdan Verstovsek
Journal:  Cancer       Date:  2022-04-06       Impact factor: 6.921

Review 8.  Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.

Authors:  Barbara Mora; Francesco Passamonti
Journal:  Curr Hematol Malig Rep       Date:  2022-09-01       Impact factor: 4.213
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.